{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/602b13db8237836e54f27141/6ab1252d1f6f5b915f9743c6?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Can Your Body Make More GLP-1 Naturally?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/602b13db8237836e54f27141/1789994035876-0a609e65-9178-49b2-a00b-eab9848783c8.jpeg?height=200","description":"<p>Question?</p><p>📢 Ask Dr. Bikman’s Digital Mind (multilingual):</p><p><a href=\"https://benbikman.com/ben-bikmans-digital-ai-mind\" rel=\"noopener noreferrer\" target=\"_blank\">https://benbikman.com/ben-bikmans-digital-ai-mind</a></p><p><br></p><p>📢 Dr. Bikman’s Community &amp; Coaching Site: <a href=\"https://insuliniq.com\" rel=\"noopener noreferrer\" target=\"_blank\">https://insuliniq.com</a></p><p><br></p><p>Summary:</p><p>Dr. Bikman explains why some people may produce an inadequate GLP-1 response and how insulin resistance could be part of the problem. Because intestinal L cells have insulin receptors, chronically elevated insulin can make these cells insulin resistant, reducing their ability to release GLP-1 and potentially creating a cycle of faster stomach emptying, higher glucose, more insulin, and further impairment of the natural GLP-1 response.</p><p><br></p><p>Ben uses this physiology to explain how he believes GLP-1 medications should be used: not simply to produce maximum weight loss, but as a temporary window in which carbohydrate cravings become easier to control. Rather than escalating automatically to the highest tolerated dose, he favors using the lowest dose that makes refined carbohydrates easier to resist while still requiring the person to exercise some choice and discipline. During that window, the goal is to establish meals centered on protein, healthy fats, and whole foods while improving sleep and resistance training.</p><p><br></p><p>Ben also addresses concerns about lean-mass loss, explaining that body-composition scans can classify losses of water, glycogen, organ fat, and even the non-fat portion of adipose tissue as “lean mass.” Ultimately, he argues that GLP-1 therapy should have an exit strategy: improve insulin sensitivity, restore the body's own GLP-1 signaling as much as possible, establish sustainable habits, and then work with a clinician to gradually reduce the medication rather than assuming it must be permanent.</p><p><br></p><p>References:</p><p>For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&amp;A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: <a href=\"https://www.benbikman.com\" rel=\"noopener noreferrer\" target=\"_blank\">https://www.benbikman.com</a></p>","author_name":"Insulin IQ"}